data keep eu pharma datapack contain global valuat
tabl performance/valu chart catalyst calendar updat weekli drug
prescript price trend updat weekli us retail prescript monthli global
combin institutional/retail data quarterli gross net price trend us dynam
retail trend latter proprietari view us retail switch/initi trend
last week sxdp vs sxxp nbi nyse pharma vs
roll week base thursday close price
azn receiv fda approv selumetinib gmab host call
ceo jan van de winkel cfo anthoni pagano note key catalyst
track expect partnership epcoritamab around
partner report darzalex sale beat consensu estim
hcm receiv fda track design surufatinib hik join barclay call
manag amneal read-across hikma drug use
intub icu palli care current high demand view
inject shortag stay readthrough amneal call
lun host call ceo dr deborah dunsir remain posit
long-term prospect vyepti like soften near-term launch
current
environ feedback ceo call gr announc failur
evobrutinib phase trial ra sle compani focu asset
develop ms go forward announc develop upcom
launch serolog test san announc diagnost
collabor luminost
chart week us nrx
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
research report prepar whole part equiti research analyst
base outsid us registered/qualifi research analyst finra
share price perform price-to-earnings valuat
updat roll basi
european pharmaceut posit barclay research summari valuat comparison larg mid smid biotech cap
note full disclosur cover compani includ detail company-specif valuat methodolog risk pleas refer http //publicresearch barcap com
close price april stock local currenc
stock rate ow overweight ew equal weight uw underweight barclay industri view european european mid cap posit
merck free float repres approxim outstand issuanc
cap stoxx stoxx cap stoxx stoxx cap stoxx stoxx ep compound-annual-growth-rate price-to-earnings price-to-earnings ifr price-to-earnings barc ifr price-to-earnings dp yield yield yield sale compound-annual-growth-rate sale compound-annual-growth-rate debt/ ebitda barc ep compound-annual-growth-rate summarymid capratingpricepric targetpotenti upsid downsid ptpt impli price-to-earnings pt impli price-to-earnings npv/ shnpv up/ down-sidelead analystnpv impli p/emarket cap bn coverag summarylarg cappricepric targetpotenti upsid downsid pt price-to-earnings prem/ impli price-to-earnings npv up/ down-sidebarc price-to-earnings shmarket cap bn pt impli price-to-earnings barc price-to-earnings adj price-to-earnings npv impli p/elead analyst price-to-earnings yield adj price-to-earnings barc price-to-earnings price-to-earnings price-to-earnings prem/ ebitda ev/ ebitda price-to-earnings ebitda ev/ ebitda perf perf eur barc ep compound-annual-growth-rate sale compound-annual-growth-rate perf eur coverag summarysmid biotechlead analystratingpricepric targetpotenti upsid downsid ptpt impli price-to-earnings pt impli price-to-earnings npv/ sh price-to-earnings price-to-earnings price-to-earnings price-to-earnings prem/ ifr price-to-earnings npv up/ down-sidenpv impli p/emarket cap bn barc adj price-to-earnings price-to-earnings yield ep compound-annual-growth-rate ep compound-annual-growth-rate sale compound-annual-growth-rate sale compound-annual-growth-rate pegfwdnet debt/ ebitda perf perf eur ev/ ebitda ev/ ebitda dp yield perf eur barc ep compound-annual-growth-rate sale compound-annual-growth-rate pegfwdnet debt/ ebitda barclay european pharmaceut
cover balaji prasad part specialti pharma coverag neutral industri view
cover emmanuel papadaki part european pharmaceut coverag posit industri view
cover emili field part european mid cap pharmaceut coverag posit industri view
merck kgaa free float repres approxim outstand issuanc
mid-cap compani calcul ev/ ebitda place ev/ ebita
cover hassan al-wakeel part european medic technolog servic coverag posit industri view
cover kristen stewart part us medic suppli devic coverag posit industri view
full disclosur cover compani includ detail company-specif valuat methodolog risk pleas refer http //publicresearch barcap com
bloomberg consensu forecast non-cov stock barclay research rate pt estim eu pharma rate stock barclay research rate pt us pharma bloomberg estim us pharma
data injectable/infus drug week end april gmab ceo/cfo call
registr link
genmab a/ ceo/cfo call earn recap give us reason
european equiti strategi earn look beyond abyss
 lundbeck a/ feedback call ceo busi seem well-posit
plc readthrough call amneal
replay barclay eu manag call seri replay detail
share price perform price-to-earnings valuat
section updat share price perform price-to-earnings valuat larg
cap coverag also provid sector price-to-earnings valuat histor rel
absolut pe yr forward eu hc eu market
rel pe perform rebas year back
eu hc pe rel eu hpc person household good
eu hc pe yr forward rel eu market
eu hc pe rel eu util
eu hc pe rel eu food beverag
market peeu healthcar healthcar rel eu mkteu healthcar rel eu healthcar rel eu healthcar rel eu food beverag barclay european
price-to-earnings rel market sxxp healthcar sxdp
price-to-earnings rel market sxxp healthcar sxdp
price-to-earnings rel market sxxp healthcar sxdp
pe pe rel sxxpazn pe rel sxdpavg rel sxxpavg rel pe pe rel sxxpbayn pe rel sxdpavg rel sxxpavg rel pe pe rel sxxpgsk pe rel sxdpavg rel sxxpavg rel sxdp barclay european
pe rel market sxxp healthcar sxdp
price-to-earnings rel market sxxp healthcar sxdp
price-to-earnings rel market sxxp healthcar sxdp
pe pe rel sxxpnovn pe rel sxdpavg rel sxxpavg rel pe pe rel sxxpnovo pe rel sxdpavg rel sxxpavg rel pe pe rel sxxprog pe rel sxdpavg rel sxxpavg rel sxdp barclay european
price-to-earnings rel market sxxp healthcar sxdp
price-to-earnings rel market sxxp healthcar sxdp
price-to-earnings rel market sxxp healthcar sxdp
pe pe rel sxxpsan pe rel sxdpavg rel sxxpavg rel pe pe rel sxxpgen pe rel sxdpavg rel sxxpavg rel pe pe rel sxxpgrf pe rel sxdpavg rel sxxpavg rel sxdp barclay european
price-to-earnings rel market sxxp healthcar sxdp
price-to-earnings rel market sxxp healthcar sxdp
price-to-earnings rel market sxxp healthcar sxdp
pe pe rel sxxphik pe rel sxdpavg rel sxxpavg rel pe pe rel sxxpipn pe rel sxdpavg rel sxxpavg rel pe pe rel sxxplun pe rel sxdpavg rel sxxpavg rel sxdp barclay european
price-to-earnings rel market sxxp healthcar sxdp
price-to-earnings rel market sxxp healthcar sxdp
price-to-earnings rel market sxxp healthcar sxdp
pe pe rel sxxpsobi pe rel sxdpavg rel sxxpavg rel pe pe rel sxxpmrk pe rel sxdpavg rel sxxpavg rel pe pe rel sxxpucb pe rel sxdpavg rel sxxpavg rel sxdp barclay european
price-to-earnings rel market sxxp healthcar sxdp
price-to-earnings rel market sxxp healthcar sxdp
price-to-earnings rel market sxxp healthcar sxdp
pe pe rel sxxpargx pe rel sxdpavg rel sxxpavg rel pe pe rel sxxpglpg pe rel sxdpavg rel sxxpavg rel pe pe rel sxxpvifn pe rel sxdpavg rel sxxpavg rel sxdp barclay european
price-to-earnings rel market sxxp healthcar sxdp
price-to-earnings rel market sxxp healthcar sxdp
price-to-earnings rel market sxxp healthcar sxdp
pe pe rel sxxphcm pe rel sxdpavg rel sxxpavg rel pe pe rel sxxpidia pe rel sxdpavg rel sxxpavg rel pe pe rel sxxpmor pe rel sxdpavg rel sxxpavg rel sxdp barclay european
section use iqvia smart us databas smart us aggreg us npa
weekli prescript data us npa us nation prescript audit npa
industri standard measur retail outflow us prescript dispens
hand consum data defin total prescript
broken nrx new prescript rrx refil prescript
channel includ npa data retail chain pharmaci independ
mail servic pharmaci standard specialti long term
databas includ non-retail channel dispens physician
hospit pharmaci clinic pharmaci closed-wal hmo home healthcar
patient break prescript need new rx
note continu patient break prescript need new
rx truli nrx patient alreadi drug accur
pictur nrx see ntbx metric next section im market dynam
us long-act insulin market nrx growth compani
us long-act insulin market share compani
us market administr
novo victoza ozemp lilli trulic us nrx share
sharetrul nrx sharevictoza nrx shareozemp nrx share farxiga azn invokana invokamet jardianc bi/lilli steglatro diabet nrxjardianc diabet jardianc nrx merck onglyza azn tradjenta lilli nesina merck onglyza azn tradjenta lilli nesina takeda barclay european pharmaceut
tivicay nrx
triumeq nrx
nrx nrx nrxtivicay nrx nrxtriumeq barclay european
biktarvi nrx
barclay research iqvia report restrict place
biktarvi mail channel assum repres prescript
 nrx sharetriumeq strsch share rht axi linear ch share rht axi share sharetriumeq strsch share rht axi linear ch share rht axi share sharetivicay total marketch share rht axi linear ch share rht axi share sharetivicay total marketch share rht axi linear ch share rht axi share ch barclay european
section use iqvia market dynam databas market dynam
also aggreg us npa prescript data us npa us nation prescript
audit npa industri standard measur retail outflow us
prescript dispens hand consum
howev unlik smart us databas previou section market dynam
take nrx rrx break granular specif
market dynam break nrx follow categori treatment
naiv patient switch patient add patient continu patient
break prescript strip last categori continu patient
break prescript creat categori call ntbx new brand rx
captur truli dynam patient market also dig switch/add
metric understand product patient switch to/from ad
truli new brand patient
market dynam data report captur us retail channel includ
mass merchandis addit mail channel captur hemophilia
immunolog multipl sclerosi long-term care captur
sanofi us la insulin franchis ntbx
us la insulin market switch/ add
novo nordisk us la insulin franchis ntbx
us str plu tivicay descovi ntbx
ntbxtrulic ntbxbyetta/bydureon ntbxtanzeum ntbxozemp ntbxrybelsu new therapi start switch to/add ntbxodefsey ntbxtriumeq ntbxbiktarvi ntbxtivicay ntbxdescovi ntbxdovato ntbxjuluca share new therapi start switch to/add class ntbxlaba/ class ntbxlaba/lama class ntbxtripl class ntbx barclay european
share new therapi start switch to/add ntbxtecfidera ntbxgilenya ntbxmavenclad ntbxmayzent ntbx barclay european
section use iqvia smart global mida databas smart
global mida databas measur volum valu trend product volum
measur number standard dose unit sold wholesal
wholesal price data collect world-wide monthli interv valu
data amount money collect wholesal unit gross
valu standard chosen currenc local currenc
 lc report use local currenc dollar sale lc local
currenc sale convert usd constant exchang rate unlik smart us
market dynam smart global mida captur retail mail long term
care non-retail channel includ chain pharmaci independ
servic pharmaci standard specialti long-term care non-feder hospit
feder facil clinic hmo home healthcar
use data look ex-u market diabet respiratori market
non-retail channel preval epogen oncolog etc also view
biosimilar penetr europ help us think upcom launch us
section provid focu particularli topic biosimilar area diabet
immunolog cancer pleas note biosimilar share/penetr data also
includ chart throughout note
basaglar share us lantu franchis
abasaglar volum share lantu franchis key eu
total eu humira valu countri biosimilar
total eu humira volum countri biosimilar
global rituximab valu countri biosimilar
global rituximab volum countri biosimilar
eu eprex known epogen procrit us biosimilars-
eu eprex known epogen procrit us biosimilars-
na hyperkalaemia veltassa lokelma volum
na hyperkalaemia veltassa lokelma valu
data constrain iqvia supplier restrict
data constrain iqvia supplier restrict
em growth compani valu
em growth compani valu
em growth compani volum
em growth compani volum
china growth compani valu
china growth compani valu
china growth compani volum
china growth compani volum
use compani report sale prescript data im calcul
us net price per prescript key drug compar gross
price im section updat quarterli reconcil quarterli
updat roll basi
use compani public clinicaltri gov bloomberg variou
sourc compil upcom catalyst stock coverag note
potenti high-impact catalyst base analysi
kestrel data hnscc regulatori submiss
danub combin treatment data reaout
submiss metastat bladder cancer combo data
pdufa date beigen zanubrutinib patient r/r
fda approv sclc base caspian data
submiss accept sbla pdufa
enhertu trastuzumab deruxtecan anticip jp approv base destini breast
full data present poseidon
anticip pdufa hf cvot base dapa-hf
us regulatori submiss neurofibramatosi type
sprint submiss accept prioriti review
regulatori submiss studi
mainten treatment adv ovarian cancer grant
prioriti review pdufa
pdufa base profound studi castration-
regulatori submiss stroke base thale
cn approv copd
readout procaid mcrpc
relapsed/refractori cll intoler
enhertu trastuzumab deruxtecan anticip regulatori submiss gastric
anticip cn regulatori approv base hf cvot data
data determine-preserv hfpef studi
data determine-reduc hfref studi
aria result allergen-induc inflamm mild
anticip regulatori approv hyperkalaemia jp
bayou readout pt-inelig stage iv urotheli
data recurr pt-res/refractori ovarian cancer
china approv lynparza germlin brca-mut
metastat breast cancer grant prioriti review
readout ovarian cancer
sponsor astella
data lung psg nsclc cn
eu regulatori submiss neurofibramatosi type
anticip eu submiss mild asthma sygma
nda tucatinib local advanc metastat
adjuv adjuv nsclc
navig data sever asthma
submit
submiss accept anaemia ckd
anticip regulatori submiss sle base
regulatori submiss sle lupu
us eu approv cvot
regulatori submiss acut ischem stroke tia
eu submiss cll
enhertu trastuzumab deruxtecan eu submiss base
enhertu trastuzumab deruxtecan data readout
anticip regulatori submiss hfref base
eu jp cn approv hf cvot
ostro data nasal polyp regulatori submiss
meltemi readout asthma adult ic
ponent readout sever eosinophil asthmat
hd ic laba chronic oc with/out addit
eu jp approv extensive-stag sclc
cn submiss extensive-stag sclc
eu jp approv extensive-stag sclc
readout stage nsclc
readout aegean data neoadjuv nsclc
cn submiss sclc base caspian data
data readout nsclc magellan
readout himalaya data liver cancer
priorit hf anticip readout chronic heart
failur patient high risk develop
eu regulatori decis brcam pancreat cancer
base polo studi
us submiss brcam ovarian cancer base
eu/jp approv base studi
mainten treatment adv ovarian cancer
asthma data denali mild/mod tyre
asthma exercise-induc bronchodil
data anaemia md
anticip cn approv mild asthma sygma
anticip data readout sever asthma
doublet combo data hnscc
propel mcrpc anticip submiss
readout anticip submiss bladder cancer
anticip submiss liver cancer
anticip submiss base aegean data
anticip submiss stage nsclc
readout anticip submiss nsclc
readout anticip submiss locoregion liver
cancer base studi
readout biliari tract cancer
jp submiss cll
readout anticip submiss adjuv breast
readout anticip submiss ckd dapa-ckd
avant data stabl copd
data anticip submiss
enhertu trastuzumab deruxtecan data bc
enhertu trastuzumab deruxtecan data low bc
anticip submiss anaemia md
anticip submiss asthma
anticip submiss sever asthma base
baltic sclc
anticip submiss recurr pt-res/refractori
ovarian cancer base data
anticip submiss nasal polyp base ostro
duo-o data avastin/imfinzi advanc ovarian
deliv data hfpef
strong data advanc solid malign
adriat data limit diseas sclc
potomac bcg data non-muscl invas bladder
niagara chemo data muscl invas bladder
adaura data adjuv nsclc
laura data local advanc egfrm stage
medley data readout rsv high-risk children
melodi data healthi late pretern term infant
miracl data asthma cn
data advanc solid tumour
tulip lte data sle
data relaps inhl
outcom trial fidelio-dkd reduc kidney failur
diseas progress diabet kidney diseas
victoria present aacr
estim eu approv mcrpc chmp posit opinion
receiv base arami
anticip fda review bla valoctocogen
roxaparvovec adult haemophilia
bla submit updat given
eu approv men nmcrpc submit
anticip fda review bla valoctocogen
roxaparvovec adult haemophilia
readout vte cancer
data indol inhl
ema approv use children venou
voyag pad readout thrombot vascular event
procedur lower extrem
invictus-vka readout non-interior studi
asteroid readout japanes adult uterin
fibroid heavi menstrual bleed
readout patent-child studi children pah
data vs chemo fcfr local advanc
ema approv use children venou
readout patent-child studi children pah
data vs chemo fcfr local advanc
flexibl vs fix dose regimen readout wamd
anticip readout galactic-hf chronic heart
failur reduc eject fraction primari complet
date registr studi jan
data relaps inhl
outcom trial figaro-dkd reduc cardiovascular
mortal morbid diabet kidney diseas cv
data read us submiss alnylam atla
rnai therapeut hemophilia rare bleed disord
asteroid read-out symptomat uterin
readout intravitr inject vs laser
therapi studi retinopathi prematur
extend life anti-vegf data kodiak
launch diffus system sclerosi
readout glioblastoma glm agil
arasen data metastat castrat sensit prostat
data stage colon cancer
long-term data solid tumour studi
trial short long term safeti treatment
castrat resist prostat cancer patient bone
signal gener studi raynaud phenomenon
trial combin zytiga xtandi cs prostat
cancer patient bone metastas
studi cf
trial dose higher approv kbq kg cs
prostat cancer patient bone metastas
trial osteosarcoma
trial hemophilia a/b patient without
trial anti-coagul therapi
trial patent-child pediatr patient pah
trial treatment hemophilia rare bleed
trial anti-coagul therapi
nsabp trial adjuv colon cancer
anticip fda approv advanc ovarian
women respond pt-base chemo regardless
biomark submiss accept
review rtor expect approv
ascend data anemia
submiss lupu nephriti
poc data copd muscl weak
poc data er breast combin therapi
submiss
data sever nasal polyposi
 data in-hous analysi on-going
expect fda decis hikma advair gener
copd vaccin proof concept data human
belantamab mafodotin bcma poc data combo mm
combin data sle
anticip eu approv follow submiss
us regulatori submiss hiv end
submiss accept prioriti review
estimate pdufa r/r mm
data readout regulatori submiss multipl
myeloma monotherapi base submiss
data announc
poc data mm nsclc mono combin therapi
data cholestat pruritu pbc
poc interim analysi uc
submiss nasal polyp
us submiss move registr
fda approv asthma submit
safeti run-in data mm combin therapi
submiss sle
pivot data btc
combo therapi lung platform
anticip submiss btc
pivot data ec
initi result gepotidacin vs ceftriaxon
azithromycin gc gepotidacin vs
nitrofurantoin uuti
patient dose announc start
contrast result tofacitinib sariumab
amber readout nsclc
anticip readout pt-resist ovarian cancer
first data mainten treatment newli
result vs placebo tofacitinib
mod/sever ra inadequ respons
result vs placebo tofacitinib
mod/sever ra inadequ respons convent
synthet dmard biolog dmard
us/uk paediatr data launch uk
plan us submiss start
potenti submiss asthma
plan submiss system sclerosi
plan submiss ra psoriasi ulcer coliti
plan submiss rheumatoid arthriti
potenti submiss anti il asthma
potenti submiss anti-tslp dab asthma
eu chmp opinion anticip file approach
data readout cml
anticip eu approv sickl cell diseas
anticip eu approv paediatr psoriasi
asthma quartz headlin result may
approv anticip
submit us decemb relaps ms monthli subcut
inject self-administ prioriti review receiv
data plan file psoriat arthriti head-to-head vs
plan us file nraxspa base prevent studi
alreadi submit eu
approv anticip
paradise-mi data effect post-acut mi cv death hf
hospit new onset hf hfpef fortihfi program
plan submiss ankylos spondyl cn
legal district court hear gilenya ipr appeal appeal
launch
presbyopia data due present ascr
spirit interim result long-term safeti studi
patient inadequately-control asthma soc
data steroid-refractori chronic graft vs host
diseas sr cgvhd manuscript submiss
merlin vs eylea regeneron namd readout
anticip regulatori decis namd
anticip approv adjuv melanoma cn
arrow data vs tremfya stelara-resist skin plaqu
anticip eu submiss hyperlidemia
anticip eu approv ded
plan file cush diseas
eu approv advanc breast cancer
anticip us submiss hfpef
result non-alcohol steatohepat
eu/jp anticip approv sma iv administr
anticip approv hf-pef base parallax
anticip fda approv hyperlidemia
us regulatori file anticip receiv breakthrough
therapi design file dec
estim pdufa liso-cel dlbcl base
anticip us pdufa nasal polyp base polyp
anticip fda target action allergan
molecula partner abicipar pegol neovascular wamd eu
anticip jp approv nr-axspa
anticip us submiss
plan file administr sma fda place partial
clinic hold base find small preclin anim studi
plan us/eu submiss advanc metastat melanoma
result mcrpc vision studi anticip
studi readout dme
anticip readout chronic gvhd
data pnh pnh start
anticip ema approv adult rm applic
submit base optimum
eu/u approv celgen ozanimod relaps ms us
plan file sma type
anticip eu approv rm monthli subcut inject
self-administ submiss accept
readout nsclc
plan file nsclc
anticip readout galactic-hf chronic heart failur
reduc eject fraction primari complet date
registr studi jan
readout hf paediatr patient panorama
plan file mdr tuberculosi
plan file csu/ciu
plan file dme
plan file cml
plan file md
plan file new formul sickl cell anaemia
plan file r/r follicular lymphoma
plan file r/r dlbcl relaps
plan file neoplasm pedia
plan file food effect free formul
plan file acut chronic gvhd
plan file auto-injector
plan file food allergi
plan file post-ami
extend life anti-vegf data kodiak
readout adjuv nsclc canopy-a
long-term extens trial rainbow retinopathi
complet aml
plan submiss dri eye
plan submiss adjuv nsclc
plan submiss hidraden suppurativa
readout sickl cell diseas patient vaso-occlus
plan file csu
plan file renal liver toxic
plan file pnh
plan file sever asthma
plan file anti-rankl mab
plan file malign myeloma combo
plan file
plan file igan
readout psoriat arthriti
readout aggress b-cell nhl belinda
plan file rett syndrom
plan submiss presbyopia
plan submiss atop dermat
plan submiss ankylos spondyl base
jp submiss aghd
estim eu jp approv chmp posit opinion
combin sema obes
includ gg-co-agonist tri-agonist result
result obes qw sema vs pbo
result obes qw sema
result obes sema intens
result obes sema qw
reach dose run-in
initi dyslipidaemia manag
steroid fxr agonist result nash
anticip us/eu approv follow submiss
first data tirzepatid
control vs tresiba
sustain fort data high dose
result obes data
readout dual gip agonist
tirzapatid non-control
readout dual gip agonist
tirzapatid vs insulin degludec
initi weekli basal insulin
result studi tirzepatid
vs semaglutid add-on metformin patient
us/eu regulatori submiss obes
data explor haem a/b irrespect
inhibitor prophylaxi bypass on-demand
explor haem a/b irrespect inhibitor
prophylaxi factor replac on-demand
data obes vs duummi medicin
result haemophilia
first human dose diabet
result vs sitagliptin patient treat
metformin
china result patient treat
diet exercis
result vs liraglutid obes patient
weight manag obes adolesc
select result heart diseas stroke
result ckd patient
focu result lt effect diabet eye diseas
b-fast data eu/jp approv ntrk
fda approv base impow select
impass data paclitaxel tnbc await
us/eu file sma type firefish type
sunfish data type prioriti review
pdufa may
eu approv takeda vedolizumab mainten
therapi moder sever activ uc crohn
archway result namd use dose
pavillion start earli
estimate eu approv ruxienc biosimilar
approv tecentriq avastin combin
sbla submitut
os result metastat urotheli
carcinoma result present esmo
eu approv cll file juli eu submiss
eu data submiss influenza fda approv
receiv oct influenza high-risk patient
eu submiss influenza post-exposur prophylaxi
fda submiss accept target pdufa
ipatun hr tnbc
nda tucatinib local advanc metastat
anticip fda review bla valoctocogen
roxaparvovec adult haemophilia
mirro result r/r aml file r/r aml
anticip us pdufa nasal polyp base polyp
eu/fda approv sc combo treatment herceptin
trastuzumab metastat breast cancer
submiss accept pdufa
estim bsufa allergan biosimilar
fda pdufa addit formul granul oral
suspens peopl one year age older
influenza post-exposur prophylaxi
prevent treatment influenza exposur
fda accept bla biocon avastin biosimilar
bsufa goal date
anticip fda target action allergan
molecula partner abicipar pegol neovascular wamd
anticip ema approv adult rm applic
submit base optimum
initi data bispecif
potenti launch amgen/allergan biosimilar mvasi ec
kaitlin data oper earli bc
impass data nabpaclitaxel neoadjuv tnbc
estim jp approv r/r alk alcl file jun
fda/eu submiss nsclc dx
estim cn approv fl file apr
estim cn approv glioblastoma file jan
estim cn approv nsclc file aug
readout autism spectrum disord
estim cn approv lupu nephriti file aug
readout hibiscu hickori cottonwood
ulcer coliti submiss uc
readout yosemit rhine ci-dm
readout prodrom mild
estim cn approv fl file sep
estim cn approv r/r fl file sep
initi lupu nephriti studi
readout castration-resist
readout tnbc hr
estim cn approv ebc file feb
estim jp approv ebc file aug
estim cn approv cll file apr
eu/u approv celgen ozanimod relaps ms
port deliveri system ranibizumab
fda/eu submiss wamd
expect us file neuromyel optica
fda/eu appov non-squam nsclc dx
data adjuv therapi high-risk
muscle-invas urotheli carcinoma surgic
result submissionin front-lin ovarian
fda approv neo adjuv nsclc base
submiss melanoma anticip base
estim cn approv essclc file feb
vial readout unfit aml
eu approv influenza file novemb
coheru anticip file bla biosim avastin late
 earli launch directli approv
bergamot readout crohn diseas
data read alnylam atla rnai therapeut
hemophilia rare bleed disord
data combin adjuv
chemo oper tnbc
polarix result dlbcl anticip file
extend life anti-vegf data kodiak
canova result r/r mm
readout tenaya lucern wet
readout gener huntington diseas
readout laurel ulcer coliti junip
data abrocitinib jade compar vs
suit defend patent right month stay
vial form merck
submiss gen meningococc vaccin
pfuda target action date apr patient
present result btki rm lieu
fda submiss use children sever
prioriti review receiv pdufa may
pivot data readout acid sphingomyelinas defici
rapid-act insulin eu submiss complet
pivot readout submiss basal cell carcinoma
pivot readout submiss late onset pomp
eu approv age group
read basal cell carcinoma
ikema data submiss rrmm
part readout pivot eosinophil esophag trial part
receiv r/r mm base icaria-mm data
anticip fda review bla valoctocogen
roxaparvovec adult haemophilia
poc read-out atop dermat
anticip approv agglutinin diseas
poc readout combo adjuv breast cancer
pivot readout year old asthma
amplitude-m inadequatelli control diet
exercis vs placebo
eu approv year old age group
eu approv age group
anticiapt approv paediatr relaps ms
anticip approv ldl-c reduct hofh
anticip approv hexaval vaccin paediatr
data nsclc
data read alnylam atla rnai
therapeut hemophilia rare bleed disord
anticip submiss haemophilia a/b
amplitude-d vs trulic inadequ
control metformin
staged-pkd data polycyst kidney diseas
anticip initi itp studi
data jade extend
amplitude- data patient inadequatelli
control metformin sulphonylurea
anticip submiss prurigo nodulari readout
anticip submiss mbc result anticip
anticip approv basal cell carcinoma us
asthma year old start
amplitude-l inadequatley control basal
insulin oral antidiabet anticip submiss
anticip submiss cervic cancer
anticip submiss acid sphingomyelinas
anticip submiss newli diagnos mm
imroz data mm inelig transplant
data polymyalgia rheumatica
anticip submiss polyarticular juvenil idiopath
data giant cell aretr
terikid pediatr relaps ms data expect
primari endpoint updat full
complet ole
os monotherapi data nsclc plu chemo
os combin data nsclc plu chemo
anticip submiss haemophilia pivot
anticip submiss autosomal-domin polycyst
anticip submiss ad pivot result exp
part readout pivot eosinophil esophag trial part
anticip submiss gaucher ert switch
anticip submiss eosinophil esophag
anticip submiss chronic spontan urticaria
anticip submiss bullou pemphigoid read-out
anticip submiss ldl-c reduct paediatr
anticip read-out allerg bronchopulmonari
aspergilliosi
anticip read-out second copd studi
anticip submiss rsv medley studi
expect complet melodi expect
complet
anticip submiss combo
anticip submiss nsclc
anticip submiss polym rheumatica
anticip submiss giant cell arter
data nsclc plu chemo vs keytruda
anticip submiss relaps ms
anticip submiss combo
anticip submiss ppm
anticip submiss spm
anticip submiss parkinson associ gba
anticip submiss earli bc acceler
anticip submiss rrm paediatr
anticip submiss crcc adjuv therapi
anticip submiss nsclc
anticip submiss us eu
anticip submiss alport syndrom
anticip submiss atop dermat
anticip submiss copd
anticip submiss asthma
anticip submiss newli diagnos mm transplant
anticip submiss aml paediatr
anticip submiss system juvenil arthriti
anticip submiss tdap booster us
anticip submiss fabri diseas
anticip submiss gaucher
anticip submiss purifi rabi vaccin
ph result cervic cancer
fda/ema decis subcutan formul
fda approv ms
data phase expans cohort
decis recommend ph dose initi expans
ph result solid tumour
end
argx fcrn ph data mg
public data medic journal
ucb fcrn ph data cidp
phase preciosa studi cirrhosi
phase studi acute-on-chron liver failur
launch scig product
fda decis gener file made
launch market end year
launch addit market
updat clinic develop program
updat us octreotid generics/eu lanreotid gener
rcc ph combo opdivo checkmat
initi phase program fop
phase data hallux valgu
initi phase trial pdac
initi ph studi spastic aesthet
initi ph studi glabellar line
phase trial
headlin result relief studi
introduc new molecul clin dev
addit ph data ad agit final
end
turn
end
ph data prnb/sanofi btk ms
ph data nsclc mono/high intens
mileston payment gsk lung interim
file exon skip
ph data rheumatoid arthritis/lupu
ph data read local advanc head neck
anticip eu submiss itp
anticip eu launch itp
anticip approv secondari hlh
ph data psoriasi full data
confirmatori phase start
ph data drug-resist epilepsi aris
adapt trial efgartigimod mg
phase result axspa
end
ph top-line result
phase data studi
ph top-line result
phase aurora trial hidraden suppurativa
ph trial complet test ferinject result
reduc hospit mortal patient
heart failur iron defici
ph affirm-ahf trial complet patient acut
guidelin updat base amber result
phase accolad trial glomerulopathi
ph heart-fid trial readout patient heart failur
phase studi commenc
phase addit readout itp
adapt ph trial readout mg
updat fcrn program
phase readout mg
mg bla file us
advanc ph trial readout itp
eu approv launch
rocella phase readout oa
studi start advanc malign mesothelioma
nda submiss cn nsclc data
interim data sanet-p pnet cn studi china
data cn studi solid tumour initi
start cn
anticip initi cn
initi us develop program
us/eu studi initi net grant fda track
earli data savoir global studi papillari rcc
interim data savannah global studi nsclc
complet regulatori discuss us eu jp
initi requir clinic studi us eu
present full exon del nsclc data
present sanet-p pnet data
second interim data gastric frutiga cn
initi global registr studi
initi cn inhl registr studi global
expans inhl us eu
interim readout biliari tract studi cn
potenti nda approv china launch epnet base
sanet-ep
initi cn inhl registr studi
expandion inhl studi us eu
anticip enrol complet savannah
anticip enrol complet frutiga cn
anticip global studi start hem malign
anticip global studi start hem malign
readout savannah global studi nsclc
studi anticip readout insomnia
studi anticip readout insomnia
ind accept fda expect
readout jp studi vasospasm-rel morbid
mortal all-caus morbid mortal
anticip submiss insomnia y/e earli
anticip ema approv adult rm idia
receiv quarterli net payment net sale
ponesimod actelion janssen submiss ema
initi acut mi studi part global agreement
antar
readout sle dose vs pbo
react readout prevent clinic deterior due
delay cerebr ischaemia patient aneurysm
confirmatori studi readout resist hypertens
ema submiss base l-mind expect mid
pivot studi frontlin dlbcl plan start mid-
bla base l-mind submit approv
data readout frontlin dlbcl exp
present expect
anticip eu approv base l-mind
primari analysi data expect b-mind
primari complet date cn studi run imab
first readout gsk contrast program exp
emmanuel papadaki phd cfa emili field cfa herebi certifi view express research report accur reflect
person view subject secur issuer refer research report part compens
directli indirectli relat specif recommend view express research report
